This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Solriamfetol

Well Researched

DNRI wakefulness drug from Axsome (acquired Sunosi from Jazz Pharma in 2022) — A-tier evidence in narcolepsy + OSA EDS, B-tier shift work,…

Aliases (6)

Sunosi · JZP-110 · ADX-N05 · ADX-N10 · (2R)-2-amino-3-phenylpropylcarbamate · (R)-2-amino-3-phenylpropyl carbamate hydrochloride

TYPICAL DOSE

75 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

Daily-safe per FDA label and clinical use

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Solriamfetol?

Solriamfetol is a dopamine-norepinephrine reuptake inhibitor (DNRI) approved by the FDA in 2019 (brand name Sunosi) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a non-amphetamine wake-promoting agent.

Key Benefits

Improves wakefulness and reduces excessive daytime sleepiness in narcolepsy and OSA, with sustained effects through the day, lower abuse potential than amphetamines, and minimal cardiovascular impact at standard doses.

Mechanism of Action

Inhibits both the dopamine transporter (DAT) and norepinephrine transporter (NET), raising synaptic dopamine and norepinephrine in wake-promoting circuits (locus coeruleus, ventral tegmental area). Unlike amphetamines, it does not significantly cause vesicular monoamine release.

▸Brand options4 known

SunosiJZP-110ADX-N05ADX-N10

StatusSchedule IV (US DEA, 2019); Rx-only most jurisdictions

Research Indications

Most Effective

~95% renal excretion as unchanged drug

minimal CYP metabolism, so very few liver-mediated drug interactions. Renal impairment matters: half-life extends 1.2× / 1.9× / 3.9× in m…

Research Protocols

Disclaimer: These are commonly discussed research protocols and not medical advice.

Goal

Dose

Frequency

Solo Use

Cycle

Goal:Renal dosing:

Dose:75 mg AM

Frequency:AM

Solo:—

Cycle:—

Peptide Interactions

L-theanine

Synergistic

200 mg AM: Tempers norepinephrine-driven anxiety/BP without blunting wake-promotion. Most-recommended adjunct.

Magnesium glycinate

Synergistic

200-400 mg AM: BP buffer + anxiety reduction.

Citicoline

Synergistic

250-500 mg AM: PFC acetylcholine support pairs well with the DA/NE drive — anecdotal cognitive synergy.

MAOIs (any)

Avoid

14-day washout BOTH directions REQUIRED. Hypertensive crisis + serotonin syndrome risk. Includes selegiline at higher doses (>10 mg/day, where MAO-A selectiv…

Stimulants (amphetamine, methylphenidate)

Avoid

Additive sympathomimetic load → BP + HR + anxiety stacking. Avoid concomitant unless explicitly directed.

Modafinil / armodafinil

Avoid

Redundant mechanism; don't stack — switch.

Bupropion

Avoid

Both NDRI → additive seizure-threshold lowering + sympathomimetic stack. Avoid.

SNRIs (venlafaxine, duloxetine)

Avoid

NE-NE additive load, BP risk. Use cautiously.

Caffeine high-dose (>300 mg/day)

Avoid

Additive HR + BP + anxiety. Keep total daily caffeine ≤200 mg if on solriamfetol.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Onset
~30-60 min, peak around 2 hr.
Peak
experience: Cleaner wakefulness than amphetamines (no jitter, no euphoria, no tunnel vision); more energizing than modafinil for most users — "brighter, more…
Taper
Gentler than amphetamine crash; shorter than modafinil's tail. Some users report mild fatigue rebound by 6-8 PM as plasma levels decline.

Side Effects & Safety 12

Side Effects

1Headache (12-16%) — usually first 1-2 weeks, typically resolves
2Nausea (6-9%) — dose-dependent, take with food helps
3Decreased appetite (6-9%) — dose-dependent; less than amphetamines but real
4Anxiety (5-9%) — more pronounced at 300 mg; norepinephrine-driven
5Insomnia (4-6%) — usually means dose taken too late in day or dose too high
6Increased heart rate (3-5%)
7Increased blood pressure (3-5%)
8Dry mouth, palpitations, irritability, agitation, dizziness, jitteriness
9Constipation, diarrhea
10Hyperhidrosis
11Bruxism
12Mood changes (mild dysphoria or mild euphoria depending on user)

When to Stop

Hypertensive episodes — clinically significant BP elevations requiring discontinuation in <2% trial subjects but real. Pharmacovigilance 2025 study (PMC12453233) flagged elevated signals for palpitations + BP elevation, especially in OSA cohort.
Major adverse cardiovascular events (MACE) — Theoretical risk from sustained BP elevation. FDA warning labels caution in patients with known CV disease, hypertension, advanced age. Long-term MACE data still maturing.
Psychiatric: Agitation, panic attacks, mania (rare), suicidal ideation (very rare; not specifically signal-elevated vs placebo)
First 2-4 weeks: Daily BP monitoring (cuff + Oura ring HR baseline). Discontinue if SBP rises >10 mmHg sustained or DBP >5 mmHg sustained.
First 8 weeks: Anxiety + insomnia tracking. If anxiety is consistent at 150 mg, drop to 75 mg or discontinue.
Renal function check at baseline and annually if continued long-term — drug is renally cleared.